Actinium Pharmaceuticals’ (ATNM) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNMFree Report) in a research report released on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $21.00 price objective on the biotechnology company’s stock.

Several other equities analysts also recently commented on ATNM. StockNews.com downgraded shares of Actinium Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, March 19th. B. Riley decreased their price target on Actinium Pharmaceuticals from $20.00 to $16.00 and set a buy rating for the company in a research note on Monday, December 11th. HC Wainwright reaffirmed a buy rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday, March 26th. Finally, Maxim Group increased their target price on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a buy rating in a research note on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus price target of $25.72.

Check Out Our Latest Research Report on ATNM

Actinium Pharmaceuticals Stock Up 9.3 %

NYSEAMERICAN ATNM opened at $8.56 on Monday. Actinium Pharmaceuticals has a 52 week low of $4.00 and a 52 week high of $9.86. The firm has a market cap of $237.63 million, a price-to-earnings ratio of -4.46 and a beta of 0.01.

Institutional Trading of Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ATNM. UBS Group AG boosted its holdings in shares of Actinium Pharmaceuticals by 76.2% in the 4th quarter. UBS Group AG now owns 3,235 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 1,399 shares in the last quarter. Royal Bank of Canada boosted its stake in Actinium Pharmaceuticals by 38.5% in the second quarter. Royal Bank of Canada now owns 6,734 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 1,871 shares in the last quarter. California State Teachers Retirement System purchased a new position in Actinium Pharmaceuticals in the second quarter worth $64,000. Boothbay Fund Management LLC acquired a new position in shares of Actinium Pharmaceuticals during the first quarter worth $96,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Actinium Pharmaceuticals during the 2nd quarter valued at $83,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

(Get Free Report)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.

Read More

Analyst Recommendations for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.